[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581718":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":36,"locations":43,"responsibleParty":66,"collaborators":41,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":41,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":41,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":41,"overallStatus":46,"whyStopped":41,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ACEIs","ACTIVE_COMPARATOR","0.3 mg\u002Fkg\u002Fdose every 8 hours orally by either a caregiver or caring nurse.",[13],"Drug: ACE Inhibitors",{"label":15,"type":10,"description":16,"interventionNames":17},"β-blockers","0.05 mg\u002Fkg\u002Fdose every 12 hours orally by either a caregiver or caring nurse",[18],"Drug: β -Blockers",[20,26],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","ACE Inhibitors",[9],[25],"Captopril",{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"β -Blockers","0.05 mg\u002Fkg\u002Fdose every 12 hours orally by either a caregiver or caring nurse.",[15],[31],"Carvedilol",[33],{"name":34,"affiliation":5,"role":35},"Manal Hamed El-Hamamsy, Prof","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":42},"Christen Said","CONTACT","+201093942389",null,"keristin.nazir21@pharma.asu.edu.eg",[44,62],{"facility":45,"status":46,"city":47,"state":41,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Faculty of Pharmacy, Ain Shams University","RECRUITING","Cairo","11566","Egypt","EG",{"type":52,"coordinates":53},"Point",[54,55],31.24967,30.06263,{"lat":55,"lon":54},[58],{"name":59,"role":39,"phone":60,"phoneExt":41,"email":61},"Aml Elkhouly, Assoc. Prof","0201060355448","Amal.Elkhouly@pharma.asu.edu.eg",{"facility":45,"status":46,"city":47,"state":41,"zip":41,"country":49,"countryCode":50,"cosmosGeoPoint":63,"geoPoint":65,"contacts":41},{"type":52,"coordinates":64},[54,55],{"lat":55,"lon":54},{"type":35,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":41,"oldOrganization":41},"keristin nazir","Teaching Assistant","100581718","phase-3-cardioprotection-on-chemotherapy-induced-cardiotoxicity-100581718",false,"NCT06853951","Cardioprotection on Chemotherapy-Induced Cardiotoxicity","The Effect of Cardioprotective Medications on Chemotherapy-Induced Cardiotoxicity in Childhood Acute Leukemia","Inclusion Criteria:\n\n* Willingness of the legal representative of research participant to participate in the study by giving \"informed consent.\"\n* Ability to take oral medication.\n* Age 2-18 years at the time of diagnosis.\n\nExclusion Criteria:\n\n* Documented allergy to cardioprotective medications","ALL","1 Year","18 Years",{"count":80,"type":81},30,"ESTIMATED","INTERVENTIONAL",[84],"PHASE3","The aim of the present study is to evaluate the protective impact of cardioprotective medications on the chemotherapy- induced cardiotoxicity.",[87],"Cardiotoxicity","2025-02-25",{"date":90,"type":91},"2025-03-03","ACTUAL",{"date":93,"type":91},"2023-07-18",{"date":95,"type":81},"2025-07-18",{"name":5,"class":6},2]